Burgeon Therapeutics

Main purpose: To evaluate the efficacy of loading different doses of BGT-002 tablets on statin therapy in reducing low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia, as well as the relationship between dose and efficacy. Secondary objectives: To evaluate the safety of BGT-002 tablets in patients with primary hypercholesterolemia; to evaluate the pharmacokinetic characteristics of BGT-002 tablets in patients with primary hypercholesterolemia.

Main research purposes: to evaluate the effect of BGT-002 on the pharmacokinetics of atorvastatin in healthy subjects; to evaluate the effect of BGT-002 on the pharmacokinetics of rosuvastatin in healthy subjects; in healthy subjects To evaluate the effect of BGT-002 on the pharmacokinetics of simvastatin in subjects; Secondary research purpose: To evaluate the safety and tolerability of subjects after oral administration of BGT-002 in combination with atorvastatin; to evaluate the safety and tolerability of subjects after oral administration of BGT-002 in combination with rosuvastatin. Acceptability; evaluate the safety and tolerability of subjects after oral administration of BGT-002 in combination with simvastatin. Exploratory purpose: To explore the pharmacokinetic characteristics of subjects after multiple oral administrations of BGT-002; to explore the pharmacodynamic characteristics of subjects after multiple oral administrations of BGT-002.

Main objective: To evaluate the safety and tolerability of BGT-002 tablets in NASH subjects Secondary objectives: 1) To evaluate the pharmacokinetic characteristics of NASH subjects after oral administration of BGT-002 tablets; 2) To assess the effect of BGT-002 on lipid metabolism in NASH subjects; 3) To assess the effect of BGT-002 on NASH subjects The role of biochemical indicators related to liver function in patients. Exploratory objectives: To assess the biomarker profile of BGT-002 in NASH subjects.